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Abstract: Diseases associated with unstable repetitive
elements in the DNA, RNA, and amino acids have
consistently revealed scientific surprises. Most diseases
are caused by expansions of trinucleotide repeats, which
ultimately lead to diseases like Huntington’s disease,
myotonic dystrophy, fragile X syndrome, and a series of
spinocerebellar ataxias. These repeat mutations are
dynamic, changing through generations and within an
individual, and the repeats can be bi-directionally
transcribed. Unsuspected modes of pathogenesis involve
aberrant loss of protein expression; aberrant over-
expression of non-mutant proteins; toxic-gain-of-protein
function through expanded polyglutamine tracts that are
encoded by expanded CAG tracts; and RNA-toxic-gain-of-
function caused by transcripts harboring expanded CUG,
CAG, or CGG tracts. A recent advance reveals that RNA
transcripts with expanded CAG repeats can be translated
in the complete absence of a starting ATG, and this
Repeat Associated Non-ATG translation (RAN-translation)
occurs across expanded CAG repeats in all reading frames
(CAG, AGC, and GCA) to produce homopolymeric proteins
of long polyglutamine, polyserine, and polyalanine tracts.
Expanded CTG tracts expressing CUG transcripts also
show RAN-translation occurring in all three frames (CUG,
UGC, and GCU), to produce polyleucine, polycysteine, and
polyalanine. These RAN-translation products can be toxic.
Thus, one unstable (CAG)N(CTG) DNA can produce two
expanded repeat transcripts and homopolymeric proteins
with reading frames (the AUG-directed polyGln and six
RAN-translation proteins), yielding a total of potentially
nine toxic entities. The occurrence of RAN-translation in
patient tissues expands our horizons of modes of disease
pathogenesis. Moreover, since RAN-translation counters
the canonical requirements of translation initiation, many
new questions are now posed that must be addressed.
This review covers RAN-translation and some of the
pertinent questions.
Introduction
Scientific surprises abound in diseases associated with unstable
repetitive elements in the DNA, RNA, and proteins. These diseases
are caused by expansions or contractions of trinucleotide, tetranu-
cleotide, pentanucleotide, dodecanucleotide, and macrosatellite
repeats (Table 1). This class of disease, including some 40 diseases
(for a complete set, see Supplementary Table 1 presented in Lo ´pez
Castel et al. [1]), has revealed several unique and unsuspected
findings: surprises include mutations that are dynamic—ever
changing both through generations and within an individual
(Table 1) [1,2]. Unsuspected modes of pathogenesis also abound,
including: aberrant loss-of-protein expression [3]; aberrant over-
expression of non-mutant proteins [4–6]; toxic-gain-of-protein
function through expanded polyglutamine tracts that are encoded
byexpandedCAGtracts[3];andRNA-toxic-gain-of-functioncaused
by transcripts harboring expanded CUG or CGG tracts [7,8]. There
is even one disease known to be caused by both a toxic-polyglutamine
and a toxic-RNA, with both arising from bidirectional transcription
across both complementary CAG and CTG repeat strands (Table 1)
[9–12]. Many regions of the genome are transcribed across both
strands, including most of the repeats associated with disease loci,
suggesting that multiple toxic entities (polyGln and toxic CUG-
RNAs) may contribute to the pathogenesis of numerous diseases
[9,12]. How many surprises remain for this field to reveal?
Discovery of Repeat Associated Non-ATG
Translation (RAN-Translation)
The lab of Dr. Ranum has just published a paper that now
reveals yet another surprise: RNA transcripts with expanded CAG
repeats can be translated in the complete absence of a starting
ATG, and this Repeat Associated Non-ATG translation (RAN-
translation) occurs across expanded CAG repeats in all reading
frames (CAG, AGC, and GCA) to produce homopolymeric
proteins of long polyglutamine, polyserine, and polyalanine
tracts [13] (Figure 1). Constructs with expanded CTG tracts
expressing CUG transcripts also show RAN-translation, which
also occurs in all three frames (CUG, UGC, and GCU), to
produce polyleucine, polycysteine (Figure 1), and polyalanine.
This counters the canonical requirements of translation initiation
[14]. RAN-translation occurs on expansion constructs that are
integrated into the genome in cells and brains, as well as in tissues
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PLoS Genetics | www.plosgenetics.org 2 March 2011 | Volume 7 | Issue 3 | e1002018of transgenic mouse models of repeat diseases. Importantly,
Ranum and colleagues show RAN-translation occurs in disease-
relevant tissues of SCA8 and DM1 patients with CAG/CTG
expansions.
Templates and Tissues for RAN-Translation
RAN-translation depends on repeat length to varying degrees
for each reading frame. Constructs containing 15–20 CAG repeats
did not express polyGln by RAN-translation, but constructs with
42–107 repeats did. PolyAla was robustly expressed with ,100
repeats, moderately with ,80 repeats, but not with 42 and 58
repeats. PolySer was detected with 58–107 but not 42 repeats. The
length dependence for CTG constructs to RAN-translate poly-
leucine, polycysteine, and polyalanine is yet to be determined.
Thus, RAN-translation is length dependent, and, for a given CAG
tract length, polyAla is expressed at the highest levels followed by
polyGln and polySer. Longer repeat tracts can express multiple
RAN-translated homopolymeric proteins. Ranum and colleagues
clearly demonstrated that all three RAN-translated proteins can be
expressed simultaneously in a single cell.
RAN-translation was shown to occur in other disease-relevant
sequence contexts, as constructs with flanking sequences from
upstream of the CAG repeat from the Huntingtin (HD),
Huntingtin-like 2 (HDL2), spinocerebellar ataxia type 3 (SCA3),
or myotonic dystrophy type 1 (DM1) loci showed robust polyGln
and polyAla and variable polySer expression in the absence of an
ATG-start codon.
The surprising observation of RAN-translation on CAG and
CUG tracts might also make one question what other repeat
sequences may be permissive for RAN-translation. For example,
might CGG or CCG repeats be RAN-translated? FXTAS,
where premutation CGG expansions at the FMR1 and the
antisense CCG tracts from FMR4 are transcribed (Table 1).
Thus far, the evidence supports a role for a toxic-RNA mode of
pathogenesis for FXTAS [8]. RAN-translation across the CGG
and CCG tracts would present polyArg, polyAla, polyGly,
polyPro, polyArg, and polyAla runs as potential toxic entities for
FXTAS.
Expansions of polyalanine and polyaspartic acid tracts can
cause disease. At least nine diseases are caused by expansions of
polyAla tracts in proteins and one is caused by expansion of an
polyaspartic acid run (Table 1; see also [1,15]). Instability in other
amino acid runs has been hypothesized to be a source of disease
[16]. In the cases where the pathogenic path is known, both loss-
of-function, gain-of-function, and dominant negative protein
pathways are evident.
Might longer repeat units like tetranucleotide or pentanucleo-
tide expansions be prone to RAN-translation? The possibility that
the CUG present within the expanded CCUG tract of DM2
transcripts may lead to pathogenic RAN-translated products is
worthy of consideration. RAN-translation across either the CCUG
or CAGG tracts would produce a set of polymeric tetrapeptides,
where each of the four possible reading frames would yield a
distinct amino acid. CCUG, when RAN-translated, would
produce CCU, GCC, UGC, and CUG, making repeated units
of the tetrapeptide (ProAlaCysLeu)n. CAGG, when RAN-
translated, would produce CAG, GCA, GGC, and AGG, making
repeated units of the tetrapeptide (GlnAlaGlyArg)n. Notably,
expansions of repeated amino acid tracts, as in the insertional
expansion mutations of the octapeptide repeat of the prion protein
(Table 1), are directly linked to prion disease: the normal PrP has
four octapeptide segments, while expanded forms can have as
many as nine additional octapeptide units. Genetic anticipation is
evident in that prion disease onset correlates with octapeptide
expansion size; with up to four extra units, the age of onset is .60
years; with five to nine extra units, the age of onset is 30–40 years
[17].
Figure 1. RUNning a RAN-gene. One DNA, two transcripts, seven possible reading frames, potentially nine toxic entities! Both CAG and CTG
transcripts could be toxic [12,38], the AUG-initiated polyGln protein reading frame can be toxic, and each of the three reading frames from either the
CAG or CUG transcript present six additional homopolymeric proteins, making a total of nine potentially toxic entities!
doi:10.1371/journal.pgen.1002018.g001
PLoS Genetics | www.plosgenetics.org 3 March 2011 | Volume 7 | Issue 3 | e1002018Products of RAN-Translation
What are the functions of tandem runs of amino acids and how
might these pertain to disease? Many vertebrate proteins contain
tandem runs of amino acids, with the vast majority being present
in DNA/RNA metabolizing factors, where the homopolymers are
thought to be involved in formation of large multi-protein
complexes [18]. Such functions may be consistent with the ability
of polyGln and polyAla proteins to form aggregates and may
suggest a pathogenic role similar to aberration in the transcrip-
tome or splicing, as with other repeat diseases [3].
Disease-specific tissues and cells showed RAN-translated
homopolymeric proteins. Antibodies developed specifically to
predicted amino acid sequences downstream of RAN-translated
SCA8-polyAla and DM1 polyGln proteins. The SCA8-polyAla
was detected in Purkinje cell soma and dendrites throughout the
cerebellum in a SCA8 mouse model and cerebellar Purkinje cells
of postmortem samples from SCA8 patients. Similarly, in DM1
mouse tissues and DM1 patient cardiac myocytes, leukocytes, and
myblasts, polyGln nuclear aggregates were detected. These were
not detected in non-disease or control mouse tissues. All of these
observations support the presence of RAN-translated proteins in
vivo and in patient tissues.
RAN-translation products may be toxic and may be linked to
disease pathology. Zu et al. showed that cells transfected with
CAG constructs that are RAN-translated to polyGln, polyAla, and
polySer showed some signs of increased apoptosis, suggesting that
RAN-translation products could be toxic to cells and may
contribute to neurodegenerative disease symptoms. However,
due to the toxicity outcome used (CAA versus CAG repeats as a
measure of RAN-translation), toxicity is potentially confounded by
any RNA-mediated toxicity. It is notable that polyAla has already
been demonstrated to be toxic to cells and may contribute to
several diseases (Table 1; see also [15]). In the case of RAN-
translation, it is unclear as to whether the polyAla, polySer, or
PolyGln is the cause of the apparent toxicity, and to what degree
this may contribute to disease.
Mechanism of RAN-Translation: Initiation,
RNA-Structure, cis-Elements, and trans-Factors
The mechanism of RAN-translation initiation is unclear. The
AUG-free CAG transcripts co-sedimented with the light polyribo-
somes. RAN-translation was sensitve to cycloheximide, which binds
to ribosomes and inhibits tranlsation elongation. It would be
interesting to learn the effect of other compounds (such as
lactimidomycin or emetine) that can differentially affect initiation
or elongation of translation [19,20] upon RAN-transation. RAN-
translation is distinct from translational frameshifting previously
reported for CAG tracts [21,22]. Exactly where along the CAG
tract initiation of RAN-translation occurs is unknown. Sites of
initiation of RAN-translation may differ between repeats and
reading frames. For example, RAN-translation of the CAG frame
yielded predominantly a distinct polyglutamine protein band with a
molecular weight similar to that of a protein initiated by an AUG
start codon just upstream of the repeat [13], suggesting that RAN-
translation initiated only at the start of the repeat sequence—either
atthefirstCAGorata non-AUGcodonjustupstreamoftherepeat.
In contrast, RAN-translation of the GCA frame yielded a tightly
spaced series of proteins, suggesting that initiation occurred at
various points along the repeat. This was confirmed by mass spec
analysis of the polyAla RAN products, which revealed a series of N-
terminal peptideswithvarying numbers ofalanine residuesanda C-
terminal fragment with the predicted C-terminal residues. Thus,
initiation or RAN-translation may vary between repeat sequences.
RNA structure is likely to be critical to RAN-translation. Non-
AUG initiation has been reported in a handful of mammalian genes
arising at various codons, including ACG, CUG, GUG, and UUG
[23]. In all cases this is the result of methionine tRNA base pairing
to a codon complimentary at only two bases. In contrast, Zu et al.
reveal that RAN-translation does not appear to initiate via an N-
terminal methionine [13]. An initiator Met-tRNA-independent
form of non-AUG translation initiation is used by certain viruses
[24]. These viruses use an internal ribosome entry site (IRES),
which recruits ribosomes and initiates translation at non-AUG sites.
Maintaining the base-pairing of the IRES pseudoknot stem-loop
structures is necessary for translation initiation. Seemingly, the
IRES structurally mimics the initiator tRNA, and manipulates the
ribosome to allow for non-AUG initiation of translation. Future
research will reveal whether the ability of expanded CAG
transcripts to assume both intra-strand hairpins and multi-branched
RNA structures [25] could be related to this viral mode of non-
AUG Met-tRNA-independent translation initiation [24]. For
example, the long r(CAG) tracts may permit folding into tRNA-
like structures that permit self-priming of translation. Based upon
the CNG tract length-dependence, Ranum and colleagues
hypothesize that the initiation of RAN-translation may involve
RNA hairpin structures [13], as long tracts of CAG and CUG
repeats that can form hairpins and multi-branched RNA structures
[25] canexpress homopolymers intheabsenceofATG-startsrepeat
sequences, while repeat sequences that cannot form hairpins do not
display RAN-translation. Further support for the role of a CAG/
CUG hairpin comes from a report that a hairpin, previously used as
a translationalblock, could,insomecontexts oftheFMR1transcript
lacking a CGG tract, lead to translation initation at GUG codons in
the hairpin stem [26]. Similar to the arrest of translation by the
Kozak hairpin [27], it was reported that expansions of either CGG
repeats or CTG repeats (but not CAG repeats) suppressed
translation in a tract length- and context- (59UTR) dependent
manner [28,29]. Notably, the finding of context-dependent
initiation in the Kozak hairpin [26], coupled with the hairpin-
forming ability of CAGand CUGrepeats, supports the possible role
of hairpins in RAN-translation. Might non-repeat interruptions of
expanded CNG repeats [25,30–32] that can disrupt intra-strand
RNA conformations [25] affect RAN-translation? What other
secondary sturctures permit RAN-translation? Curiously, in the
absence but not the presence of an AUG, it was preliminarily
suggested that a CUG codon downstream of an expanded in-frame
CUG tract may initiate low levels of translation; however, this was
not followed up [29]. The precise RNA structural features involved
in RAN-translation need to be elucidated.
Repeat context may affect RAN-translation. Flanking RNA
sequence may affect the capacity or efficiency of RAN-translation.
For example, Zu et al. [13] found that brain RAN-translation in the
polyglutamine frame was undetectable in the HD or SCA3 context, a
littleintheDM1andHDL2sequence,andalotintheSCA8context.
Such effects may be due to the varied RNA structures assumed by the
same CNG tract in different gene contexts [25]. Might the
polyproline-encoding CCG tract immediately 39 of the HD CAG
tract or the polyglycine-encoding GGC tract adjacent to the SBMA
CAG tract [33,34] modulate RAN-translation?
Future Avenues—There Are Many
Clearly, the canonical rules of translation do not apply to
CAGNCTG expansion tracts since, in the absence of an ATG codon,
expanded CAG and CTG trinucleotide repeats can express
homopolymeric expansion proteins in all three frames (Figure 1).
RAN-translation may be a tissue-specific phenomenon, much like the
PLoS Genetics | www.plosgenetics.org 4 March 2011 | Volume 7 | Issue 3 | e1002018instability of the repeats, which can vary by .5,700 repeats between
tissues [2,35]. Production of antibodies to predicted downstream
reading frames of each DNA strand of the expanded disease loci
should reveal whether RAN-translation is possible at these loci.
Further research is needed to reveal the true pathogenic role of any of
the RAN-translation products. Understanding the mechanism of
RAN-translation is going to be an area of active research.
Many new questions now arise with the discovery of RAN-
translation. In addition to the immediate questions like ‘‘Do RAN-
translated proteins contribute to disease pathology?’’ and ‘‘What is
the mechanism of RAN-translation?’’ or ‘‘How many of the
phenotypes in the cell and mouse models of trinucleotide repeat
disease are the result of RNA-translated proteins rather than the
supposed polyGln or CUG RNA?’’. Other questions include:
‘‘What other trinucleotide repeats (disease-associated or otherwise)
might be RAN-translated?’’ or ‘‘Might non-trinucleotide repeats
like tetranucleotide, pentanucleotide or other satellites undergo
RAN-translation?’’ or ‘‘Might certain non-repetitive codons suffice
to initiate RAN-translation?’’ or ‘‘Might the amino acid sequences
downstream of the RAN-translated homopolymeric tracts con-
tribute to disease?’’ or ‘‘What stop codons are used for the RAN-
translated products?’’ or ‘‘Might there be a natural function of
RAN-tranlslated proteins?’’ or ‘‘what proteins are involved in
RAN-translation?’’ or ‘‘Might a depletion of amino acid pools be
expected if RAN-translation exceeds the cells capacity, could this
be related to the reduced plasma amino acids in either HD or
DM1 patients to RAN-translation [36,37]?’’, and many others.
Conclusions
Validation of these initial and exciting observations of RAN-
translation [13] and their extension to clinical disease in patients will
make thisa landmarkpaper that willreshape a large bodyof research
on nucleotide repeat disorders, as well as re-focus our understanding
of translational initiation and concepts of gene products/DNA
stretch. The discovery of RAN-translation is likelyto put many labs in
many research areas in the RUNning for these answers.
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